Indonesia campaigns for pharmaceutical after liberalization
In this article (5)
The government is intensifying efforts to support the country’s longstagnant pharmaceutical industry after opening up the sector to foreign investment in its latest revision to the negative investment list (DNI).
The efforts were evident at a dialog on “Expediting the Development of Indonesia’s Pharmaceutical Industry” organized by the Investment Coordinating Board (BKPM) on Thursday that gathered together players in the pharmaceutical industry and its related sectors.
“Most of the existing companies make medicines, whereas the raw material businesses is small. Roughly 90 percent of raw material for the pharmaceutical industry is imported from India or China. We have to change this,” BKPM investment monitoring and implementation deputy chairman Azhar Lubis said during the event.
In a bid to encourage the raw material industry, the government has revised the DNI, which lists the sectors restricted to foreign investment. Following the revision, the government now allows 100 percent foreign ownership in pharmaceutical companies, from 85 percent previously.
Following the issuance of the regulation, no fresh interests on raw material sector have been expressed by foreign investors, Azhar said. However, there have been 18 new licenses for investments in the pharmaceutical industry issued by BKPM from January to September worth Rp 2.1 trillion.
Apart from campaigning for investment in pharmaceutical factories, the BKPM will also push research and development (R&D) in the sector to encourage new innovations in new medicines that are locally made, Azhar added, citing R&D centers in Singapore and Europe.
“However, there have been 18 new licenses for investments in the pharmaceutical industry issued by BKPM from January to September worth Rp 2.1 trillion.”
However, industry players said the problem with investment in the pharmaceutical sector lay in the fact that there was a relatively small number of hospitals and doctors for whom the medicines would be distributed.
“Boosting the industry does not only mean pushing for medicine production and factories. What’s also needed is hospitals, doctors and clinics as the infrastructure to feed the pharmaceutical industry,” said International Pharmaceutical Manufacturers Group (IPMG) executive director Parulian Simanjuntak.
Investments in the pharmaceutical sector have stagnated in recent years, reaching just Rp 8.9 trillion from January 2011 to September 2016, BKPM data shows. Also, there are only 214 pharmaceutical companies in Indonesia, most of which make medicines. Just a few of them manufacture raw material for pharmaceuticals.
“If production [of raw material] were to start in Indonesia, it would take around three years to really get going and it would definitely cost more than importing from other countries,” said Arustiyono, the director of supervision and therapeutic product distribution at the Food and Drug Monitoring Agency (BPOM).
“The research and development phase for the chemical reactions would itself take a year,” he added.
The pharmaceutical industry is 70 percent dominated by local players, including privately-owned Kalbe Farma and state-owned Kimia Farma, among others.
“The stimulus package for raw material factory investments will bring about a positive impact for the pharmaceutical industry because the source for materials will shift to local sources. This will inoculate the industry from the rupiah’s fluctuations,” Kalbe Farma corporate secretary Vidjongtius said. “In this way, medicine production costs can be more controlled. This, however, is a medium to long-term project.”
Questions & Answers
Q.What percentage of raw material for Indonesia’s pharmaceutical industry is currently imported, and from which countries does it mainly come?
What percentage of raw material for Indonesia’s pharmaceutical industry is currently imported, and from which countries does it mainly come?
Roughly 90 percent of raw material for the pharmaceutical industry is imported. These raw materials primarily come from India or China, highlighting the country's current reliance on foreign sources.
Q.What is the primary concern raised by industry players regarding investment in Indonesia's pharmaceutical sector, despite efforts to boost production?
What is the primary concern raised by industry players regarding investment in Indonesia's pharmaceutical sector, despite efforts to boost production?
Industry players believe the main problem is the relatively small number of hospitals and doctors available. These are essential infrastructure for distributing medicines, suggesting that production alone is insufficient.
Q.How long would it take for local raw material production to become operational in Indonesia, and what is a key challenge identified with this transition?
How long would it take for local raw material production to become operational in Indonesia, and what is a key challenge identified with this transition?
It would take around three years for local raw material production to truly get going. A key challenge is that it would definitely cost more than importing from other countries, with the R&D phase alone taking a year.
Q.What impact do local players foresee from new investment in raw material factories on the cost of medicine production?
What impact do local players foresee from new investment in raw material factories on the cost of medicine production?
Local players anticipate that new investment will shift material sources to local suppliers. This change is expected to help control medicine production costs by inoculating the industry from rupiah fluctuations.
Reader pulse
Is liberalising pharma investment a smart move?
16,117 votes so far